Synthekine
PrivateLast Round
Series C
Jan 6, 2023
Total Funding Raised
$289.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Synthekine operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Series C round in January 2023.
Synthekine is a biotechnology company that develops engineered cytokine therapeutics aimed at creating disease-optimized treatments through targeted protein engineering and immunological insights for cancer and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synthekine Comparables
Compare Synthekine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Medicenna Therapeutics Corp | 87% | |
| Asher Biotherapeutics | 86% | |
| Bright Peak Therapeutics | 86% |
For institutional investors. Book with your work email.
Synthekine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 6, 2023 | ||||
| Series B | Jun 10, 2021 | ||||
| Series A | Sep 17, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synthekine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B, Series C, Series A |
| Deerfield Management | Series C, Series B |
| Janus Henderson Group | Series C, Series B |
| RA Capital Management | Series C, Series B, Series A |
| TCG Crossover | Series B |
| Omega Funds | Series C, Series B |
| The Chernin Group | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 33% MoM, reaching 6.1K.
- Oct 31, 2025
Presenting initial clinical data for STK-012 at SITC 2025.
For institutional investors. Book with your work email.
Synthekine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synthekine's valuation, stock price, and market status.
Is Synthekine a public or private company?
Synthekine is a private company.
What is the current stock price of Synthekine?
Synthekine is a private company, so its shares have no public market price. Caplight tracks Synthekine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synthekine worth (valuation)?
Valuation information for Synthekine is not publicly available.
Can I buy Synthekine stock?
Synthekine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synthekine's last funding round?
Synthekine's most recent funding round was Series C on January 6, 2023.
Who are the main investors in Synthekine?
Key investors in Synthekine include The Column Group, Deerfield Management, Janus Henderson Group, The Chernin Group, Canaan Partners.
Will Synthekine IPO soon?
No public IPO plans have been announced for Synthekine.
How can I track Synthekine secondary market activity?
Caplight tracks bids, offers, and trades in Synthekine's shares on secondary markets.